期刊文献+

不同钙浓度透析液对血透患者肾性骨病疗效观察

下载PDF
导出
摘要 目的探究血透患者应用不同钙浓度透析液治疗对肾性骨病发生的影响情况。方法选择血透患者60例作为研究对象,分为对照组与观察组两组,每组患者30例。对照组30例应用1.25mmol/L的钙离子浓度透析液治疗,观察组30例应用1.5mmol/L的钙离子浓度透析液治疗,对比两组肾性骨病症状发生情况、骨密度改善情况以及各项生化指标改变情况。结果观察组透析3个月后、透析半年后的PTH、AKP以及SP的值均显著低于对照组,差异具有统计学意义(P<0.05);观察组透析三个月后、透析半年后的SCa值以及透析半年后手指骨密度的值显著低于对照组,差异具有统计学意义(P<0.05);观察组肾性骨病发生率显著低于对照组,差异具有统计学意义(P<0.05)。结论应用高浓度钙浓度透析液治疗血透患者,可有效降低肾性骨病发生率,降低骨密度减少量以及对各生化指标影响程度,值得在临床上广泛推广。
作者 甄颖 刘山
出处 《哈尔滨医药》 2020年第4期337-338,共2页 Harbin Medical Journal
  • 相关文献

参考文献6

二级参考文献44

  • 1Thanh-Mai Vo,Sinee Disthabanchong.Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?[J].World Journal of Cardiology,2014,6(5):216-226. 被引量:5
  • 2Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phos phorus, and PTH: the Dialysis Outcomes and Practice Pat terns Study (DOPPS)[J]. Am J Kidney Dis, 2008, 52(3): 519 53O.
  • 3Melamed ML, Eustace JA, Plantinga L, et al. Changes in ser- um calcium, phosphate,, and PTH and the risk of death in inci dent dialysis patients: a longitudinal study[J]. Kidney Int, 2006, 70(2): 351 357.
  • 4Kidney Disease: Improving Global Outcomes (KDIGO) CKD- MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [J]. Kidney lnt, 2009, 76(113): 8% $130.
  • 5Block GA, Klassen PS, Lazarus JM, et al. Mineral metabo- lism, mortality, and morbidity in maintenance hemodialysis [J]. J Am Soc Nephrol, 2004, 15(8) : 2208-2218.
  • 6Basile C. Calcium mass balances in bicarbonate hemodialysis [J]. lnt J Nephrol, 2011, 2111= 540592.
  • 7Phelps KR, Mason DL, Stote KS. Phosphate homeostasis, parathyroid hormone, and fibroblast growth factor 23 in stages 3 and 4 chronic kidney disease[J]. Clin Nephrol, 20/6, 85 (5) :251-261.
  • 8王质刚,顾汉卿.血液透析的基本原理∥王质刚.血液净化学[M].第3版.北京:北京科学技术出版社,2010.5-13.
  • 9Fukagawa M, Komaba H, Onishi Y, et al. Mineral metabo- lism management in hemodialysis patients with secondary hy- perparathyroidism in Japan: baseline data from the MBD-5D [J]. Am J Nephrol, 2011, 33(5) : 427 437.
  • 10Locatell F, Covic A, Chazot C, et al. Optimal composition of the dialysate, with emphasis on its influence on blood pressure [J]. Nephrol Dial Transplant, 2004, 19(4).. 785 796.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部